BIOMAT Database Logo BIOMAT Database Logo

In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. 1990

J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285.

UCLA-P3 human lung adenocarcinoma cells were grown in nude mice and given repetitive treatments of a monoclonal antibody-Vinca alkaloid immunoconjugate. Although this therapy resulted in a greater than 4-fold reduction in mean tumor mass of the established tumors, some animals experienced a reinitiation of tumor growth after cessation of conjugate treatment. Two such animals were treated again with high doses of monoclonal antibody-Vinca but one of the tumors was no longer regressed by the drug conjugate. The tumor was excised, enzymatically dissociated, and grown in tissue culture. Cultured cells were reimplanted in nude mice and subjected to further therapy with a monoclonal antibody-Vinca conjugate. The resulting tumors were also refractory to the immunoconjugate therapy. This cycle was repeated for a total of three times and resulted in the serial in vivo selection of three conjugate resistant variants. The mechanism responsible for the in vivo resistance of human tumor cells to the monoclonal antibody-Vinca immunoconjugate is unknown but does not appear to involve antigen modulation, altered tumor cell growth rate, or an apparent decrease in tumor targeting in vivo. The resistance was also not accompanied by any detectable elevation in multidrug resistance 1 mRNA or P-glycoprotein expression. Significantly, the resistance pattern was observed only in vivo and was not maintained by cells grown in vitro.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells.
July 1985, Cancer research,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates.
January 1988, Cancer immunology, immunotherapy : CII,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
April 1992, Cancer research,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts.
October 1983, Cancer treatment reports,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody.
January 1995, Cancer investigation,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB.
October 1991, Pharmaceutical research,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.
June 1979, Cancer research,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Monoclonal antibody immunoconjugates for cancer treatment.
June 1989, Current opinion in immunology,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells.
March 2004, Molecular cancer therapeutics,
J J Starling, and R S Maciak, and N A Hinson, and J Hoskins, and B C Laguzza, and R A Gadski, and J Strnad, and L Rittmann-Grauer, and S V DeHerdt, and T F Bumol
Monoclonal antibody-drug/toxin immunoconjugates in transplantation.
February 1989, Transplantation proceedings,
Copied contents to your clipboard!